Abstract
Three cases of multiple myeloma treated with thalidomide are presented which highlight therapeutic dilemmas presented by therapy with this new agent. The difficulty of stem cell collection during thalidomide therapy is illustrated. The question of continuation of thalidomide after attainment of a plateau or remission is discussed and the management of neuropathy considered. Thalidomide, being a novel drug, presents a number of therapeutic issues that have yet to be resolved.
Copyright 2001 by W.B. Saunders Company.
MeSH terms
-
Adult
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects
-
Angiogenesis Inhibitors / therapeutic use*
-
Drug Therapy, Combination
-
Female
-
Glucocorticoids / therapeutic use
-
Hematopoietic Stem Cell Mobilization
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Peripheral Nervous System Diseases / chemically induced
-
Prednisone / therapeutic use
-
Remission Induction
-
Thalidomide / administration & dosage
-
Thalidomide / adverse effects
-
Thalidomide / therapeutic use*
Substances
-
Angiogenesis Inhibitors
-
Glucocorticoids
-
Thalidomide
-
Prednisone